Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide mechanism of action in obesity
NCT04311411Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tirzepatide in obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Calorie Intake at 3 weeks. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04311411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311411.